Literature DB >> 26286937

Phenotypic Screening for Friedreich Ataxia Using Random shRNA Selection.

M Grazia Cotticelli1, Fabio Acquaviva2, Shujuan Xia3, Avinash Kaur1, Yongping Wang3, Robert B Wilson4.   

Abstract

Friedreich ataxia (FRDA) is an autosomal recessive neuro- and cardio-degenerative disorder for which there are no proven effective treatments. FRDA is caused by decreased expression and/or function of the protein frataxin. Frataxin chaperones iron in the mitochondrial matrix and regulates the iron-sulfur cluster (ISC) assembly complex. ISCs are prosthetic groups critical for the function of the Krebs cycle and the mitochondrial electron transport chain. Decreased expression of frataxin is associated with decreased ISC assembly, mitochondrial iron accumulation, and increased oxidative stress, all of which contribute to mitochondrial dysfunction. In media with beta-hydroxybutyrate (BHB) as carbon source, primary FRDA fibroblasts grow poorly and/or lose viability over several days. We screened a random, short-hairpin-RNA (shRNA)-expressing library in primary FRDA fibroblasts and identified two shRNAs that reverse the growth/viability defect in BHB media. One of these two clones increases frataxin expression in primary FRDA fibroblasts, either as a vector-expressed shRNA or as a transfected short-interfering RNA (siRNA).
© 2015 Society for Laboratory Automation and Screening.

Entities:  

Keywords:  Friedreich ataxia; library; shRNA; siRNA; therapeutics

Mesh:

Substances:

Year:  2015        PMID: 26286937     DOI: 10.1177/1087057115600433

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  2 in total

1.  Natural and Induced Mitochondrial Phosphate Carrier Loss: DIFFERENTIAL DEPENDENCE OF MITOCHONDRIAL METABOLISM AND DYNAMICS AND CELL SURVIVAL ON THE EXTENT OF DEPLETION.

Authors:  Erin L Seifert; Aniko Gál; Michelle G Acoba; Qipei Li; Lauren Anderson-Pullinger; Tunde Golenár; Cynthia Moffat; Neal Sondheimer; Steven M Claypool; György Hajnóczky
Journal:  J Biol Chem       Date:  2016-10-25       Impact factor: 5.157

2.  Identification of p38 MAPK as a novel therapeutic target for Friedreich's ataxia.

Authors:  M Grazia Cotticelli; Shujuan Xia; Avinash Kaur; Daniel Lin; Yongping Wang; Eric Ruff; John W Tobias; Robert B Wilson
Journal:  Sci Rep       Date:  2018-03-22       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.